UBS AM’s Translate Bio, Inc. Common Stock TBIO Stock Holding History

UBS AM’s Portfolio TBIO Stock Details TBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-38,029	Closed	-$1.05M	–	2787
2021 Q2	$1.05M	Buy	38,029 +4,119	+12%	+$80.9K	﹤0.01%	2187
2021 Q1	$559K	Sell	33,910 -11,090	-25%	-$253K	﹤0.01%	2347
2020 Q4	$829K	Buy	45,000 +7,300	+19%	+$131K	﹤0.01%	2079
2020 Q3	$513K	Buy	37,700 +19,000	+102%	+$293K	﹤0.01%	2128
2020 Q2	$335K	Buy	+18,700	New	+$282K	﹤0.01%	2251
2018 Q4	–	Sell	-41,400	Closed	-$414K	–	2841
2018 Q3	$414K	Hold	41,400	–	–	﹤0.01%	2162
2018 Q2	$524K	Buy	+41,400	New	+$500K	﹤0.01%	2078

UBS AM's TBIO Position: Q3 2021 in Review

UBS AM sold out of Translate Bio, Inc. Common Stock (TBIO) in Q3 2021, closing a stake of 38,029 shares — an estimated $1.05M sold.

UBS AM first reported a position in TBIO in Q2 2018 and held it in 7 quarters. The position peaked at $1.05M in Q2 2021. 0 funds tracked by Wall St. Rank hold TBIO as of Q3 2021.

UBS AM reported no remaining Translate Bio, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
UBS AM sold 38,029 Translate Bio, Inc. Common Stock shares in Q3 2021, an estimated $1.05M.
UBS AM first reported a position in Translate Bio, Inc. Common Stock in Q2 2018 and held it in 7 quarters.
UBS AM's Translate Bio, Inc. Common Stock position peaked at $1.05M in Q2 2021.
0 funds tracked by Wall St. Rank held Translate Bio, Inc. Common Stock as of Q3 2021.

Based on UBS AM's 13F filing for Q3 2021, filed 15 Nov 2021.